Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Anika Therapeutics (NASDAQ:ANIK) with a price target of $37.
May 09, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barrington Research maintains an Outperform rating on Anika Therapeutics with a $37 price target.
The reaffirmation of an Outperform rating and a $37 price target by Barrington Research suggests a positive outlook for Anika Therapeutics. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100